Trial Profile

A phase IB/IIA trial evaluating MBS8 in combination with an oncology drug

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 26 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MBS 8 (Primary) ; Antineoplastics
Indications Solid tumours
Focus Therapeutic Use

Most Recent Events

26 Jan 2023 New trial record
20 Oct 2022 According to a MonTa Biosciences media release, the investment will in addition, secure the completion of a planned phase IB/IIA trial with MBS8 in combination with an oncology drug currently approved in several indications, Data from the ongoing phase 1 study support support these findings.this study is expected to be initiated during 2023, with the first patient treated by Q4 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com